Neurocrine Biosciences, Inc. (NBIX)
| Previous Close | 139.83 |
| Open | 140.90 |
| Bid | 140.97 x 100 |
| Ask | 141.34 x 100 |
| Day's Range | 139.39 - 141.69 |
| 52 Week Range | 89.04 - 148.37 |
| Volume | |
| Avg. Volume | 908,056 |
| Market Cap | 14.202B |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | 38.45 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 29, 1995 |
| 1y Target Est | N/A |
- PR Newswire
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today presented the CAHtalyst™ Pediatric Phase 3 clinical study baseline characteristics data for children and adolescents with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency enrolled in the study, along with CAHtalog™ Registry data assessing glucocorticoid treatment patterns in pediatric and adult patients with CAH.
- PR Newswire
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2024 and provided an update on its 2024 financial guidance.
- PR Newswire
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the U.S. Food and Drug Administration has approved INGREZZA® SPRINKLE (valbenazine) capsules, a new oral granules formulation of INGREZZA® (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease.1 INGREZZA SPRINKLE provides an alternative administration option for those who experience dysphagia or have difficulty swallowing.
